Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY 4.0Frontiers in Microbiology

Natural products regulate gut microbiota and SCFA metabolism in IBD: mechanisms and therapeutic potential

  • Beihui He1,2
  • Yuqian Xu1
  • Yujin Wang1
  • Zhiyun Pan1
  1. 1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
  2. 2School of Life Sciences, Zhejiang Chinese Medical University
Read full textPDFDOICite

Abstract

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic relapsing inflammatory condition of the gastrointestinal tract. Over the past few decades, the global incidence of this disease has continued to rise, imposing a heavy socioeconomic burden. IBD is typically characterized by gut microbiota dysbiosis and reduced short-chain fatty acids (SCFAs) levels, which in turn lead to impaired intestinal barrier function and decreased immune tolerance. Multiple studies have shown that natural products, including polysaccharides, polyphenols, alkaloids, and terpenoids, can modulate the gut microbiota in IBD, with changes in SCFA concentrations observed in some preclinical studies. These effects have been associated with alterations in bacterial taxa such as Faecalibacterium prausnitzii , Bifidobacterium , and Christensenella minuta . These findings suggest that natural products may regulate the gut microbiota–SCFA metabolic axis; however, the direct causal relationships among changes in microbial composition, SCFA concentrations, and anti-inflammatory effects remain to be established. This review summarizes current mechanisms and translational opportunities for natural products targeting the microbiota-SCFA axis in IBD.

Related

  1. Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential
    Yonghao Li, Lu Zhou, Ruixue Huang +6
    Frontiers in MicrobiologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMC
  2. Gut microbiota- and probiotic-derived bioactive metabolites: mechanisms, evidence, and therapeutic potential in metabolic disorders
    Oghenerobor B. Akpor, Ayotunde O. Ajinde
    Frontiers in Cellular and Infection MicrobiologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMCEurope PMC
  3. Gut Microbiota-Host Redox Crosstalk: Molecular Mechanisms, Disease Pathogenesis, and Therapeutic Interventions.
    Shuaihu Chen, Yulong Yin, Jie Yin +1
    Antioxidants (Basel, Switzerland)Peer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  4. Salidroside Regulates Energy Metabolism Reprogramming to Suppress Tumor Proliferation: Mechanisms and Therapeutic Implications
    Haolin Wang, Yuxin Du
    MetabolitesPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMC
  5. The m6A methyltransferase METTL3 in intervertebral disc degeneration: from molecular mechanisms to therapeutic potential
    Yi-Chun Zhou, Xiang-Song Xiang, Geng Li +2
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC

Cite

BibTeXRIS
BibTeX
@article{he2026natural,
  title = {{Natural products regulate gut microbiota and SCFA metabolism in IBD: mechanisms and therapeutic potential}},
  author = {Beihui He and Yuqian Xu and Yujin Wang and Zhiyun Pan},
  journal = {Frontiers in Microbiology},
  year = {2026},
  month = oct,
  doi = {10.3389/fmicb.2026.1942374},
  url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1942374/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Natural products regulate gut microbiota and SCFA metabolism in IBD: mechanisms and therapeutic potential
AU  - Beihui He
AU  - Yuqian Xu
AU  - Yujin Wang
AU  - Zhiyun Pan
PY  - 2026
DA  - 2026/10/14
JO  - Frontiers in Microbiology
DO  - 10.3389/fmicb.2026.1942374
UR  - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1942374/full
AB  - Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic relapsing inflammatory condition of the gastrointestinal tract. Over the past few decades, the global incidence of this disease has continued to rise, imposing a heavy socioeconomic burden. IBD is typically characterized by gut microbiota dysbiosis and reduced short-chain fatty acids (SCFAs) levels, which in turn lead to impaired intestinal barrier function and decreased immune tolerance. Multiple studies have shown that natural products, including polysaccharides, polyphenols, alkaloids, and terpenoids, can modulate the gut microbiota in IBD, with changes in SCFA concentrations observed in some preclinical studies. These effects have been associated with alterations in bacterial taxa such as Faecalibacterium prausnitzii , Bifidobacterium , and Christensenella minuta . These findings suggest that natural products may regulate the gut microbiota–SCFA metabolic axis; however, the direct causal relationships among changes in microbial composition, SCFA concentrations, and anti-inflammatory effects remain to be established. This review summarizes current mechanisms and translational opportunities for natural products targeting the microbiota-SCFA axis in IBD.
SN  - 1664-302X
ER  -